European Journal of Cancer
Volume 46, Issue 3 , Pages 625-635 , February 2010

Multimodal approach using oncolytic adenovirus, cetuximab, chemotherapy and radiotherapy in HNSCC low passage tumour cell cultures

  • João D. Dias

      Affiliations

    • Cancer Gene Therapy Group, Molecular Cancer Biology Program and Transplantation Laboratory and Haartman Institute and Finnish Institute for Molecular Medicine, University of Helsinki, Helsinki, Finland
    • HUSLAB, Helsinki University Central Hospital, Helsinki, Finland
    • ,
  • Kilian Guse

      Affiliations

    • Cancer Gene Therapy Group, Molecular Cancer Biology Program and Transplantation Laboratory and Haartman Institute and Finnish Institute for Molecular Medicine, University of Helsinki, Helsinki, Finland
    • HUSLAB, Helsinki University Central Hospital, Helsinki, Finland
    • ,
  • Petri Nokisalmi

      Affiliations

    • Cancer Gene Therapy Group, Molecular Cancer Biology Program and Transplantation Laboratory and Haartman Institute and Finnish Institute for Molecular Medicine, University of Helsinki, Helsinki, Finland
    • HUSLAB, Helsinki University Central Hospital, Helsinki, Finland
    • ,
  • Minna Eriksson

      Affiliations

    • Cancer Gene Therapy Group, Molecular Cancer Biology Program and Transplantation Laboratory and Haartman Institute and Finnish Institute for Molecular Medicine, University of Helsinki, Helsinki, Finland
    • HUSLAB, Helsinki University Central Hospital, Helsinki, Finland
    • ,
  • Dung-Tsa Chen

      Affiliations

    • Biostatistics Division, Department of Interdisciplinary Oncology, Moffitt Cancer Center and Research Institute, University of South Florida, Tampa, USA
    • ,
  • Iulia Diaconu

      Affiliations

    • Cancer Gene Therapy Group, Molecular Cancer Biology Program and Transplantation Laboratory and Haartman Institute and Finnish Institute for Molecular Medicine, University of Helsinki, Helsinki, Finland
    • HUSLAB, Helsinki University Central Hospital, Helsinki, Finland
    • ,
  • Mikko Tenhunen

      Affiliations

    • Department of Oncology, Helsinki University Central Hospital, Helsinki, Finland
    • ,
  • Ilkka Liikanen

      Affiliations

    • Cancer Gene Therapy Group, Molecular Cancer Biology Program and Transplantation Laboratory and Haartman Institute and Finnish Institute for Molecular Medicine, University of Helsinki, Helsinki, Finland
    • HUSLAB, Helsinki University Central Hospital, Helsinki, Finland
    • ,
  • Reidar Grénman

      Affiliations

    • Department of Otorhinolaryngology – Head and Neck Surgery and Medical Biochemistry, Turku University and Turku University Central Hospital, Turku, Finland
    • ,
  • Mikko Savontaus

      Affiliations

    • Turku Centre for Biotechnology, Department of Medicine, University of Turku, Turku, Finland
    • ,
  • Sari Pesonen

      Affiliations

    • Cancer Gene Therapy Group, Molecular Cancer Biology Program and Transplantation Laboratory and Haartman Institute and Finnish Institute for Molecular Medicine, University of Helsinki, Helsinki, Finland
    • HUSLAB, Helsinki University Central Hospital, Helsinki, Finland
    • ,
  • Vincenzo Cerullo

      Affiliations

    • Cancer Gene Therapy Group, Molecular Cancer Biology Program and Transplantation Laboratory and Haartman Institute and Finnish Institute for Molecular Medicine, University of Helsinki, Helsinki, Finland
    • HUSLAB, Helsinki University Central Hospital, Helsinki, Finland
    • These authors contributed equally to this work.
    • Corresponding Author InformationCorresponding author: Address: Biomedicum, Haartmaninkatu 8, 00014 University of Helsinki, Helsinki, Finland. Tel.: +11 358 919125464; fax: +11 358 919125155.
    • ,
  • Akseli Hemminki

      Affiliations

    • Cancer Gene Therapy Group, Molecular Cancer Biology Program and Transplantation Laboratory and Haartman Institute and Finnish Institute for Molecular Medicine, University of Helsinki, Helsinki, Finland
    • HUSLAB, Helsinki University Central Hospital, Helsinki, Finland
    • These authors contributed equally to this work.
    • Corresponding Author InformationCorresponding author: Address: Biomedicum, Haartmaninkatu 8, 00014 University of Helsinki, Helsinki, Finland. Tel.: +11 358 919125464; fax: +11 358 919125155.

Received 27 August 2009 ,Accepted 12 November 2009.

References 

  1. Prince ME, Ailles LE. Cancer stem cells in head and neck squamous cell cancer. J Clin Oncol. 2008;26(17):2871–2875
  2. Fuertesa MA, Castillab J, Alonsoa C, Perez JM. Cisplatin biochemical mechanism of action: from cytotoxicity to induction of cell death through interconnections between apoptotic and necrotic pathways. Curr Med Chem. 2003;10(3):257–266
  3. Pil PM, Lippard SJ. Specific binding of chromosomal protein HMG1 to DNA damaged by the anticancer drug cisplatin. Science. 1992;256(5054):234–237
  4. Rebillard A, Lagadic-Gossmann D, Dimanche-Boitrel MT. Cisplatin cytotoxicity: DNA and plasma membrane targets. Curr Med Chem. 2008;15(26):2656–2663
  5. Grem JL. 5-Fluorouracil: forty-plus and still ticking. A review of its preclinical and clinical development. Invest New Drugs. 2000;18(4):299–313
  6. Noordhuis P, Holwerda U, Van der Wilt CL, et al. 5-Fluorouracil incorporation into RNA and DNA in relation to thymidylate synthase inhibition of human colorectal cancers. Ann Oncol. 2004;15(7):1025–1032
  7. Li L, Story M, Legerski RJ. Cellular responses to ionizing radiation damage. Int J Radiat Oncol Biol Phys. 2001;49(4):1157–1162
  8. Pao W, Miller VA, Politi KA, et al. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med. 2005;2(3):e73
  9. Dempke WC, Heinemann V. Resistance to EGF-R (erbB-1) and VEGF-R modulating agents. Eur J Cancer. 2009;45(7):1117–1128
  10. Reya T, Morrison SJ, Clarke MF, Weissman IL. Stem cells, cancer, and cancer stem cells. Nature. 2001;414(6859):105–111
  11. Prince ME, Sivanandan R, Kaczorowski A, et al. Identification of a subpopulation of cells with cancer stem cell properties in head and neck squamous cell carcinoma. Proc Natl Acad Sci USA. 2007;104(3):973–978
  12. Dean M, Fojo T, Bates S. Tumour stem cells and drug resistance. Nat Rev Cancer. 2005;5(4):275–284
  13. Kanerva A, Hemminki A. Modified adenoviruses for cancer gene therapy. Int J Cancer. 2004;110(4):475–480
  14. Anders M, Christian C, McMahon M, McCormick F, Korn WM. Inhibition of the Raf/MEK/ERK pathway up-regulates expression of the coxsackievirus and adenovirus receptor in cancer cells. Cancer Res. 2003;63(9):2088–2095
  15. Bauerschmitz GJ, Guse K, Kanerva A, et al. Triple-targeted oncolytic adenoviruses featuring the cox2 promoter, E1A transcomplementation, and serotype chimerism for enhanced selectivity for ovarian cancer cells. Mol Ther. 2006;14(2):164–174
  16. Fueyo J, Gomez-Manzano C, Alemany R, et al. A mutant oncolytic adenovirus targeting the Rb pathway produces anti-glioma effect in vivo. Oncogene. 2000;19(1):2–12
  17. Sherr CJ. Cancer cell cycles. Science. 1996;274(5293):1672–1677
  18. Erjala K, Sundvall M, Junttila TT, et al. Signaling via ErbB2 and ErbB3 associates with resistance and epidermal growth factor receptor (EGFR) amplification with sensitivity to EGFR inhibitor gefitinib in head and neck squamous cell carcinoma cells. Clin Cancer Res. 2006;12(13):4103–4111
  19. Ranki T, Kanerva A, Ristimaki A, et al. A heparan sulfate-targeted conditionally replicative adenovirus, Ad5.pk7-Delta24, for the treatment of advanced breast cancer. Gene Ther. 2007;14(1):58–67
  20. Rajecki M, Kiviharju-af Hallstrom TM, Hakkarainen T, et al. Mre11 inhibition by oncolytic adenovirus associates with autophagy and underlies synergy with ionizing radiation. Int J Cancer. 2009;125(10):2441–2449
  21. Doody JF, Wang Y, Patel SN, et al. Inhibitory activity of cetuximab on epidermal growth factor receptor mutations in non small cell lung cancers. Mol Cancer Ther. 2007;6(10):2642–2651
  22. Dorr W, Bassler S, Reichel S, Spekl K. Reduction of radiochemotherapy-induced early oral mucositis by recombinant human keratinocyte growth factor (palifermin): experimental studies in mice. Int J Radiat Oncol Biol Phys. 2005;62(3):881–887
  23. Chou T-CTP. Analysis of combined drug effects: a new look at a very old problem. Trends Paramacol Sci. 1983;4:450–454
  24. Baumann M, Krause M, Hill R. Exploring the role of cancer stem cells in radioresistance. Nat Rev Cancer. 2008;8(7):545–554
  25. Kish JA, Ensley JF, Jacobs J, et al. A randomized trial of cisplatin (CACP)+5-fluorouracil (5-FU) infusion and CACP+5-FU bolus for recurrent and advanced squamous cell carcinoma of the head and neck. Cancer. 1985;56(12):2740–2744
  26. Nyati MK, Morgan MA, Feng FY, Lawrence TS. Integration of EGFR inhibitors with radiochemotherapy. Nat Rev Cancer. 2006;6(11):876–885
  27. Bonner JA, Harari PM, Giralt J, et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. New Engl J Med. 2006;354(6):567–578
  28. Okegawa T, Li Y, Pong RC, et al. The dual impact of coxsackie and adenovirus receptor expression on human prostate cancer gene therapy. Cancer Res. 2000;60(18):5031–5036
  29. Hussein MR, Cullen K. Molecular biomarkers in HNSCC: prognostic and therapeutic implications. Expert Rev Anticancer Ther. 2001;1(1):116–124
  30. Khuri FR, Nemunaitis J, Ganly I, et al. A controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer. Nat Med. 2000;6(8):879–885
  31. Lamfers ML, Idema S, Bosscher L, et al. Differential effects of combined Ad5-delta 24RGD and radiation therapy in in vitro versus in vivo models of malignant glioma. Clin Cancer Res. 2007;13(24):7451–7458
  32. Vermorken JB, Trigo J, Hitt R, et al. Open-label, uncontrolled, multicenter phase II study to evaluate the efficacy and toxicity of cetuximab as a single agent in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck who failed to respond to platinum-based therapy. J Clin Oncol. 2007;25(16):2171–2177
  33. Vincenzi B, Schiavon G, Silletta M, Santini D, Tonini G. The biological properties of cetuximab. Crit Rev Oncol Hematol. 2008;68(2):93–106
  34. Schmidt-Ullrich RK, Valerie K, Fogleman PB, Walters J. Radiation-induced autophosphorylation of epidermal growth factor receptor in human malignant mammary and squamous epithelial cells. Radiat Res. 1996;145(1):81–85
  35. Schmidt-Ullrich RK, Mikkelsen RB, Dent P, et al. Radiation-induced proliferation of the human A431 squamous carcinoma cells is dependent on EGFR tyrosine phosphorylation. Oncogene. 1997;15(10):1191–1197
  36. Van Schaeybroeck S, Karaiskou-McCaul A, Kelly D, et al. Epidermal growth factor receptor activity determines response of colorectal cancer cells to gefitinib alone and in combination with chemotherapy. Clin Cancer Res. 2005;11(20):7480–7489
  37. Dittmann K, Mayer C, Fehrenbacher B, et al. Radiation-induced epidermal growth factor receptor nuclear import is linked to activation of DNA-dependent protein kinase. J Biol Chem. 2005;280(35):31182–31189
  38. Hart LS, Yannone SM, Naczki C, et al. The adenovirus E4orf6 protein inhibits DNA double strand break repair and radiosensitizes human tumor cells in an E1B–55K-independent manner. J Biol Chem. 2005;280(2):1474–1481
  39. Yan DH, Chang LS, Hung MC. Repressed expression of the HER-2/c-erbB-2 proto-oncogene by the adenovirus E1a gene products. Oncogene. 1991;6(2):343–345
  40. Bauerschmitz GJ, Ranki T, Kangasniemi L, et al. Tissue-specific promoters active in CD44+CD24-/low breast cancer cells. Cancer Res. 2008;68(14):5533–5539
  41. Eriksson M, Guse K, Bauerschmitz G, et al. Oncolytic adenoviruses kill breast cancer initiating CD44+CD24-/low cells. Mol Ther. 2007;15(12):2088–2093
  42. Kirn D. Clinical research results with dl1520 (Onyx-015), a replication-selective adenovirus for the treatment of cancer: what have we learned?. Gene Ther. 2001;8(2):89–98
  43. Aiuti A, Cattaneo F, Galimberti S, et al. Gene therapy for immunodeficiency due to adenosine deaminase deficiency. New Engl J Med. 2009;360(5):447–458
  44. Yla-Herttuala S. Phase III trial: Ad-Tk gene therapy for malignant glioma. In:  Therapy HG editors. ESGCT 2008 invited presentations. Brugge: Mary Ann Liebert Inc.; 2008;p. 1060–1075
  45. Kanerva A, Mikheeva GV, Krasnykh V, et al. Targeting adenovirus to the serotype 3 receptor increases gene transfer efficiency to ovarian cancer cells. Clin Cancer Res. 2002;8(1):275–280
  46. Dmitriev I, Krasnykh V, Miller CR, et al. An adenovirus vector with genetically modified fibers demonstrates expanded tropism via utilization of a coxsackievirus and adenovirus receptor-independent cell entry mechanism. J Virol. 1998;72(12):9706–9713
  47. Wu H, Seki T, Dmitriev I, et al. Double modification of adenovirus fiber with RGD and polylysine motifs improves coxsackievirus-adenovirus receptor-independent gene transfer efficiency. Hum Gene Ther. 2002;13(13):1647–1653
  48. Kanerva A, Zinn KR, Chaudhuri TR, et al. Enhanced therapeutic efficacy for ovarian cancer with a serotype 3 receptor-targeted oncolytic adenovirus. Mol Ther. 2003;8(3):449–458
  49. Suzuki K, Fueyo J, Krasnykh V, et al. A conditionally replicative adenovirus with enhanced infectivity shows improved oncolytic potency. Clin Cancer Res. 2001;7(1):120–126

PII: S0959-8049(09)00843-0

doi: 10.1016/j.ejca.2009.11.005

European Journal of Cancer
Volume 46, Issue 3 , Pages 625-635 , February 2010

Article Tools

* Image Usage & Resolution